$SSKN
STRATA Skin Sciences, Inc.

2020 Form 10-K Financial Statement

#000105151421000018 Filed on March 25, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $23.09M $8.900M $31.59M
YoY Change -26.9% 11.81% 5.8%
Cost Of Revenue $8.956M $2.770M $11.32M
YoY Change -20.86% -4.15% -11.14%
Gross Profit $14.13M $6.130M $20.27M
YoY Change -30.27% 20.91% 18.4%
Gross Profit Margin 61.21% 68.88% 64.17%
Selling, General & Admin $16.94M $5.970M $22.28M
YoY Change -23.98% 11.59% 14.78%
% of Gross Profit 119.82% 97.39% 109.91%
Research & Development $1.274M $210.0K $1.002M
YoY Change 27.15% -8.7% -5.92%
% of Gross Profit 9.01% 3.43% 4.94%
Depreciation & Amortization $2.000M $1.060M $2.693M
YoY Change -25.73% -15.87% -24.42%
% of Gross Profit 14.15% 17.29% 13.29%
Operating Expenses $18.21M $6.190M $23.28M
YoY Change -21.78% 10.73% 13.7%
Operating Profit -$4.076M -$60.00K -$3.010M
YoY Change 35.42% -88.46% -10.28%
Interest Expense $211.0K -$80.00K $515.0K
YoY Change -59.03% -27.27% -54.9%
% of Operating Profit
Other Income/Expense, Net -$61.00K $0.00 -$929.0K
YoY Change -93.43% -100.0% -1.38%
Pretax Income -$4.137M -$550.0K -$3.939M
YoY Change 5.03% 27.91% -8.33%
Income Tax $275.0K -$40.00K -$149.0K
% Of Pretax Income
Net Earnings -$4.412M -$520.0K -$3.790M
YoY Change 16.41% 205.88% -6.03%
Net Earnings / Revenue -19.11% -5.84% -12.0%
Basic Earnings Per Share -$0.13 -$0.11
Diluted Earnings Per Share -$0.13 -$15.80K -$0.11
COMMON SHARES
Basic Shares Outstanding 33.61M 32.90M 31.98M
Diluted Shares Outstanding 33.61M 31.98M

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.60M $8.130M $8.130M
YoY Change 30.38% -50.7% -50.7%
Cash & Equivalents $10.60M $8.129M $8.130M
Short-Term Investments
Other Short-Term Assets $7.840M $8.010M $8.010M
YoY Change -2.12% 1383.33% 1383.33%
Inventory $3.440M $3.027M $3.030M
Prepaid Expenses
Receivables $2.940M $4.386M $4.390M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $24.83M $23.56M $23.56M
YoY Change 5.39% 1.49% 1.51%
LONG-TERM ASSETS
Property, Plant & Equipment $6.520M $5.369M $6.680M
YoY Change -2.4% 1.28% 26.04%
Goodwill $8.803M
YoY Change 0.0%
Intangibles $7.955M
YoY Change -18.54%
Long-Term Investments
YoY Change
Other Assets $280.0K $347.0K $350.0K
YoY Change -20.0% -18.93% -18.6%
Total Long-Term Assets $21.95M $23.79M $23.78M
YoY Change -7.7% -2.09% -2.14%
TOTAL ASSETS
Total Short-Term Assets $24.83M $23.56M $23.56M
Total Long-Term Assets $21.95M $23.79M $23.78M
Total Assets $46.78M $47.34M $47.34M
YoY Change -1.18% -0.35% -0.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.760M $1.880M $1.880M
YoY Change 46.81% 6.58% 6.82%
Accrued Expenses $5.060M $5.134M $5.450M
YoY Change -7.16% 14.09% 21.11%
Deferred Revenue $2.832M
YoY Change 34.92%
Short-Term Debt $7.280M $7.280M $7.280M
YoY Change 0.0%
Long-Term Debt Due $1.480M $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $18.84M $17.43M $17.43M
YoY Change 8.09% 102.37% 102.2%
LONG-TERM LIABILITIES
Long-Term Debt $1.050M $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $740.0K $178.0K $1.260M
YoY Change -41.27% -54.12% 223.08%
Total Long-Term Liabilities $1.790M $178.0K $1.260M
YoY Change 42.06% -97.64% -83.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.84M $17.43M $17.43M
Total Long-Term Liabilities $1.790M $178.0K $1.260M
Total Liabilities $20.89M $18.69M $18.69M
YoY Change 11.77% 14.95% 14.94%
SHAREHOLDERS EQUITY
Retained Earnings -$214.6M
YoY Change 1.8%
Common Stock $33.00K
YoY Change 10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.89M $28.65M $28.65M
YoY Change
Total Liabilities & Shareholders Equity $46.78M $47.34M $47.34M
YoY Change -1.18% -0.35% -0.36%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$4.412M -$520.0K -$3.790M
YoY Change 16.41% 205.88% -6.03%
Depreciation, Depletion And Amortization $2.000M $1.060M $2.693M
YoY Change -25.73% -15.87% -24.42%
Cash From Operating Activities $2.096M $1.110M $2.229M
YoY Change -5.97% 0.91% -23.03%
INVESTING ACTIVITIES
Capital Expenditures $2.159M -$1.410M $115.0K
YoY Change 1777.39% 182.0% -106.53%
Acquisitions $0.00
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$2.159M -$1.410M -$2.791M
YoY Change -22.64% 176.47% 56.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net $0.00 $7.571M
YoY Change -100.0% 152.37%
Cash From Financing Activities 2.546M -300.0K -296.0K
YoY Change -960.14% -102.62%
NET CHANGE
Cash From Operating Activities 2.096M 1.110M 2.229M
Cash From Investing Activities -2.159M -1.410M -2.791M
Cash From Financing Activities 2.546M -300.0K -296.0K
Net Change In Cash 2.483M -600.0K -858.0K
YoY Change -389.39% -201.69% -106.91%
FREE CASH FLOW
Cash From Operating Activities $2.096M $1.110M $2.229M
Capital Expenditures $2.159M -$1.410M $115.0K
Free Cash Flow -$63.00K $2.520M $2.114M
YoY Change -102.98% 57.5% -54.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17845000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
243180000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
244831000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1195000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1633000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
697000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
1936000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1880000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2764000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4386000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2944000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4690000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5134000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15962000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
274000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
184000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1610000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1810000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5523326
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5881396
CY2019Q4 us-gaap Assets
Assets
47343000
CY2020Q4 us-gaap Assets
Assets
46778000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
23555000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
24831000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8129000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10604000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-858000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2483000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15629000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16487000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18112000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33801045
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32932273
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32932273
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33801045
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
33000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; text-indent: 0.55pt; font-style: italic; font-weight: bold;">Concentration of Credit Risks</div><div style="text-align: justify;">Financial instruments which subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and accounts receivable. The Company deposits cash and cash equivalents and restricted cash in major financial institutions in the US which, at times exceeds Federal Deposit Insurance Corporation and Securities Investor Protection Corporation limits. The Company performs periodic evaluations of the relative credit standing of these institutions. The Company is of the opinion that the credit risk in respect of these balances is immaterial. In addition, the Company performs periodic credit evaluation and establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of customers. (See also <font style="font-weight: bold; font-style: italic;">Accounts receivable</font> above).</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">With the exception of the Company&#8217;s international distributor, as described in <font style="font-style: italic;">Note 18</font>, <font style="font-weight: bold;">Significant Customer</font>&#160;<font style="font-weight: bold;">Concentrations</font>, the balance of the Company&#8217;s trade receivables does not represent a substantial concentration of credit risk. Most of the Company&#8217;s sales are generated in North America, to a large number of customers.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts.</div></div>
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2262000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2832000
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
155000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
209000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
115000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
8956000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
11316000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-58000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
20000
CY2019Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
51000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
21000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-38000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
21000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
254000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
389000
CY2019 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-111000
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
254000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-86000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
129000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
254000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-111000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47113000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
48054000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-25000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
125000
CY2020Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
51000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
43433000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
45819000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
896000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
992000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48308000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47113000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
850000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
808000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
254000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
815000
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
667000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
178000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
248000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
240000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2693000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1975000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4503000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3585000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1715000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1193000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
891000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1410000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6345000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7955000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16100000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1410000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1410000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9755000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-8145000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1410000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
705000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-414000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7898000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10275000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2020Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2020Q4 us-gaap Goodwill
Goodwill
8803000
CY2019Q4 us-gaap Goodwill
Goodwill
8803000
CY2019 us-gaap Gross Profit
GrossProfit
20270000
CY2020 us-gaap Gross Profit
GrossProfit
14134000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4137000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3939000
CY2020Q4 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
171000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-869000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-827000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1195000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
407000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-149000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
275000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-106000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-272000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
221000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
377000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-104000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
733000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-570000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
116000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
884000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1352000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1036000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-444000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
634000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
417000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
233000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-144000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-210000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-247000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7955000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6345000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-515000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-61000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
766000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
211000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
376000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
495000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
225000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
225000
CY2019Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2651000
CY2020Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2949000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3444000
CY2019Q4 us-gaap Inventory Net
InventoryNet
3027000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-3790000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2159000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2791000
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
242000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
176000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
186000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1255000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
371000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
456000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46778000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47343000
CY2020Q4 us-gaap Liabilities
Liabilities
20886000
CY2019Q4 us-gaap Liabilities
Liabilities
18690000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17434000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18838000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
2528000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
10000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
568000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1050000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1478000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
452000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1478000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10000
CY2019Q4 us-gaap Noncurrent Assets
NoncurrentAssets
47343000
CY2020Q4 us-gaap Noncurrent Assets
NoncurrentAssets
46778000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2229000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2096000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-4412000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2546000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-296000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-929000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-61000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020 us-gaap Open Tax Year
OpenTaxYear
2016
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
436000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
371000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1079000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
710000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1078000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2020 us-gaap Operating Expenses
OperatingExpenses
18210000
CY2019 us-gaap Operating Expenses
OperatingExpenses
23280000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
448000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
448000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
988000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1314000
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
318000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
326000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-3010000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-4076000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
200976000
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
200976000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
347000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
178000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2103
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2103
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
331000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
513000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214561000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218973000
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7571000
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1002000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1274000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7508000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7500000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23090000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31586000
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
115000
CY2019Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
324000
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
108000
CY2019Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
209000
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
1.87
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P8Y0M11D
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P1Y0M18D
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
1.87
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y8M8D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3105000
CY2019Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3193000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2528000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
87000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
170000
CY2019 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
228000
CY2020 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
186000
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
238000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
232000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
113000
CY2020 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
67000
CY2019 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
222000
CY2020Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
26000
CY2019Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
62000
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-weight: bold;">Reclassification</div><div style="text-align: justify;">Certain reclassifications from the prior year presentation have been made to conform to the current year presentation.</div></div>
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
7275000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23374000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21331000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5529000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5369000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
43000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
90000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9038000
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12003000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1195000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1633000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.94
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0053
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5292888
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3442501
CY2020Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7275000
CY2019Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7275000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33609922
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25892000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
28653000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
31248000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-weight: bold;">Use of Estimates</div><div style="text-align: justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. The more significant estimates include (1) revenue recognition, in regard to deferred revenues and the contract term and valuation allowances of accounts receivable, (2) the inputs used in the impairment analyses of goodwill, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets (6) the fair value of financial instruments, including derivative instruments and warrants, (7) the inventory reserves, (8) state sales and use tax accruals and (9) warranty claims.</div></div>
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
407000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1195000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33609922
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31978665
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31978665
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q2 dei Entity Public Float
EntityPublicFloat
23624112
CY2020 dei Entity Registrant Name
EntityRegistrantName
STRATA Skin Sciences, Inc.
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001051514
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33801045
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q4 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
209000
CY2020Q4 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
108000
CY2020 sskn Number Of Types Of Arrangements
NumberOfTypesOfArrangements
2
CY2019 sskn Reclassification Of Reimbursements From Selling And Marketing Expenses To Revenues
ReclassificationOfReimbursementsFromSellingAndMarketingExpensesToRevenues
779000
CY2020 sskn Reclassification Of Reimbursements From Selling And Marketing Expenses To Revenues
ReclassificationOfReimbursementsFromSellingAndMarketingExpensesToRevenues
485000
CY2020 sskn Lease Automatic Renewal Period
LeaseAutomaticRenewalPeriod
P1Y
CY2019Q4 sskn Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
2046000
CY2020Q4 sskn Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
1450000
CY2019Q4 sskn Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
331000
CY2020Q4 sskn Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
249000
CY2020Q4 sskn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
272000
CY2019Q4 sskn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
350000
CY2019Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
578000
CY2020Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
607000
CY2020 sskn Increase Decrease Of Lease Liabilities Arising From Obtaining Right Of Use Assets
IncreaseDecreaseOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
CY2019 sskn Increase Decrease Of Lease Liabilities Arising From Obtaining Right Of Use Assets
IncreaseDecreaseOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
1632000
CY2020 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.612
CY2020 sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
0
CY2020Q4 sskn Delayed Payment To Vendors
DelayedPaymentToVendors
678000
CY2020 sskn Conversion Of Convertible Preferred Stock Amount
ConversionOfConvertiblePreferredStockAmount
0
CY2019 sskn Conversion Of Convertible Preferred Stock Amount
ConversionOfConvertiblePreferredStockAmount
0
CY2020Q4 sskn Preferred Stock Stated Value Per Share
PreferredStockStatedValuePerShare
1000
CY2020 sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.0976
CY2019 sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.0976
CY2019 sskn Impairment Of Lasers Placed In Service
ImpairmentOfLasersPlacedInService
30000
CY2020 sskn Impairment Of Lasers Placed In Service
ImpairmentOfLasersPlacedInService
24000
CY2020 sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
2133000
CY2019 sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
2676000
CY2019 sskn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-241000
CY2020 sskn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-312000
CY2019 sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
174000
CY2019 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.642
CY2019 sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
4577
CY2020 sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
368
CY2020 sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-48.59
CY2019 sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-42.24
CY2020Q4 sskn Proceeds Due From Credit Card Transactions
ProceedsDueFromCreditCardTransactions
10000
CY2019Q4 sskn Proceeds Due From Credit Card Transactions
ProceedsDueFromCreditCardTransactions
21000

Files In Submission

Name View Source Status
0001051514-21-000018-index-headers.html Edgar Link pending
0001051514-21-000018-index.html Edgar Link pending
0001051514-21-000018.txt Edgar Link pending
0001051514-21-000018-xbrl.zip Edgar Link pending
ex_23-1.htm Edgar Link pending
ex_31-1.htm Edgar Link pending
ex_31-2.htm Edgar Link pending
ex_32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form_10-k.htm Edgar Link pending
image00001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sskn-20201231.xml Edgar Link completed
sskn-20201231.xsd Edgar Link pending
sskn-20201231_cal.xml Edgar Link unprocessable
sskn-20201231_def.xml Edgar Link unprocessable
sskn-20201231_lab.xml Edgar Link unprocessable
sskn-20201231_pre.xml Edgar Link unprocessable